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Rapport de synthèse 
Comparaison des effets vasculaires et tubulaires rénaux de plusieurs 
antagonistes des récepteurs de !'angiotensine II en combinaison avec un 
diurétique thia:zidique chez l'humain 
Objectif : Le but de ce travail était d'investiguer si les antagonistes des récepteurs 
AT1 de !'angiotensine II (ARA2) entraînent un blocage équivalent des récepteurs au 
niveau vasculaire et au niveau rénal, en particulier lorsque le système rénine-
angiotensine est stimulé par l'administration d'un diurétique thiazidique. 
Méthode : trente volontaires masculins en bonne santé ont participé à cette étude 
randomisée, contrôlée, en simple insu. Nous avons mesuré les variations de pression 
artérielle, d'hémodynamique rénale ainsi que la réponse tubulaire rénale à une 
perfusion d'angiotensine II 3ng/kg/min administrée sur 1 heure. Ceci avant 
traitement puis après sept jours d'administration, 24 heures après la dernière dose 
de médicament. Nous avons comparé l'irbésartan 300 mg seul ou en association 
avec 12.5 ou 25 mg d'hydrochlorothiazide. (irbésartan 300/12.5 ; irbésartan 
300/25). Nous avons également comparé les effets de l'irbésartan 300/25 au 
losartan 100 mg, au valsartan 160 mg ainsi qu'à l'olmésartan 20 mg, tous 
administrés avec 25 mg d'hydrochlorothiazide. Chaque participant a été randomisé 
pour recevoir 2 traitements de 7 jours espacés d'une période d'une semaine sans 
tra.itement. 
Résultats : La réponse de la pression artérielle à !'angiotensine II exogène était 
bloquée >90% avec l'irbésartan 300 mg seul ou en association avec le diurétique. Il 
en était de même avec l'olmésartan 20/25. Par contre le blocage n'était que de 60% 
environ dans les groupes valsartan 160/25 et losartan 100/25. Au niveau rénal, 
!'angiotensine II exogène réduisait le flux plasmatique rénal de 36% en pré-
traitement. Dans les groupes recevant l'irbésartan 300 mg et l'olmésartan 20 mg 
associés à l'hydrochlorothiazide 25 mg, la vasoconstriction rénale était bloquée 
presque entièrement alors qu'elle ne l'était que partiellement avec le valsartan 
160/25 et le losartan 100/25 (34 et 45%, respectivement). En pré-traitement, au 
niveau tubulaire, !'angiotensine II exogène réduisait le volume urinaire de 84% et 
l'excrétion urinaire de sodium de 65 %. Les effets tubulaires n'étaient que 
partiellement bloqués par l'administration d'ARA2. 
Conclusion : Ces\ résultats démontrent que les ARA2 aux doses maximales 
recommandées ne h,loquent pas aussi efficacement les récepteurs AT1 au niveau 
tubulaire qu'au nivé~u vasculaire. Cette observation pourrait constituer une 
justification à l'hypothèse selon laquelle des doses plus importantes d'ARA2 seraient 
nécessaires afin d'obtenir une meilleure protection d'organe. De plus, nos résultats 
confirment qu'il y a d'importantes différences entre les ARA2, relatives à leur capacité 
d'induire un blocage prolongé sur 24 heures des récepteurs AT 1 au niveau vasculaire 
et tubulaire. 
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Comparative vascular and renal tubular effects of angiotensin 
Il receptor blockers combined with a thia:zide diuretic 
in humans 
Lionel Coltamai, Marc Maillard, Alexandra Simon, Bruno Vogt and 
Michel Burnier 
Objective The goal of this study was to investi gate whether 
angiotensin Il receptor blockers (ARBs) induce a 
comparable blockade of AT1 receptors in the vasculature 
and in the kidney when the renin-angiotensin system is 
activated by a thiazide diuretic. 
Method Thirty individuals participated in this randomized, 
controlled, single-blind study. The blood pressure and renal 
hemodynamic and tubular responses to a 1-h infusion of 
exogenous angiotensin Il (Ang Il 3 ng/kg per min) were 
investigated before and 24 h after a 7-day administration of 
either irbesartan 300 mg alone or in association with 12.5 or 
25 mg hydrochlorothiazide (HCTZ). lrbesartan 300/25 mg 
was also compared with losartan 1 OO mg, valsartan 160 mg, 
and olmesartan 20 mg ail in association with 25 mg HCTZ. 
Each participant received two treatments with a 1 -week 
washout period between treatments. 
Results The blood pressure response to Ang Il was blocked 
by more than 90% with irbesartan alone or in association 
with HCTZ and with olmesartan/HCTZ and by nearly 60% 
with valsartan/HCTZ and losartan/HCTZ (P< 0.05). ln the 
kidney, Ang Il reduced renal plasma flow by 36% at baseline 
(P<0.001). lrbesartan ± HCTZ and olmesartan/HCTZ 
blocked the renal hemodynamic response to Ang Il nearly 
completely, whereas valsartan/HCTZ and losartan/HCTZ 
only blunted this effect by 34 and 45%, respectively. At the 
tubular level, Ang Il significantly reduced urinary volume 
Introduction 
Pharmacologically, angiotensin receptor blockers (ARBs) 
have been characterized essentially by their ability to 
inhibit the blood pressure (BP) response to exogenous 
angiotensin I or II dose-dependently or to induce a 
reactive rise in plasma renin activity [1]. Clinically, how-
ever, the dose recommendations for their clinical use 
have been based on their antihypertensive efficacy rather 
than on their profile of receptor blockade. Yet, studies 
have demonstrated that the recommended doses of sev-
eral angiotensin II (Ang II) receptor antagonists do not 
provide a full blockade of Ang II type 1 (AT1) receptors 
around the clock and not even at peak and that there are 
significant differences in the time profile of Ang II 
This study was presented orally al the meeting of the European Society of 
Hypertension. 
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(-84%) and urinary sodium excretion (-65%) (P<0.01). 
These tubular effects of Ang Il were only partially blunted by 
the administration of ARBs. 
Conclusion These data demonstrate that ARBs prescribed 
at their recommended doses do not block renal tubular AT1 
receptors as effectively as vascular receptors do. This 
observation may account for the need of higher doses of 
ARB for renal protection. Moreover, our results confirm thaf 
there are significant differences between ARBs in their 
capacity to induce a sustained vascular and tubular 
blockade of Ang Il receptors. J Hypertens 28:520-526 © 
201 O Wolters Kluwer Health 1 Lippincott Williams & Wilkins. 
Journal of Hypertension 201 0, 28:520-526 
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receptor blockade among ARBs [2-4]. Moreover, several 
clinical studies have suggested that ARBs may provide 
clinical benefits beyond their effect on BP contrai [5-7]. 
These pressure-independent beneficial effects of ARBs 
have been attributed in part to the blockade of tissue 
renin-angiotensin systems (RAS) [7]. Thus, several 
investigators have proposed either to combine ARBs 
with an angiotensin-converting enzyme (ACE) inhibitor 
[8-10] or to use higher doses of ARBs than those recom-
mended for BP contrai [11-14] in order to obtain a 
greater and longer-lasting blockade of the system and 
hence to provide a better organ protection. 
Although the results of the Ongoing Telmisartan Alone 
and in combination with Ramipril Global Endpoint Trial 
(ONTARGET) did not support the hypothesis of a 
reduced morbidity and mortality with the use of an 
DOl:10.1097/HJH.Ob013e3283346be1 
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association of an ARB and an ACE inhibitor [11,15,16], 
several recent studies have shown that the use of higher 
doses of ARB or a more intense blockade of the RAS 
induce a greater decrease in proteinuria in patients with 
diabetic or nondiabetic nephropathies [11-14,17,18]. 
The greater impact of high doses of ARBs on proteinuria 
may be due to the fact that Ang II is abundantly produced 
within the kidney and intrarenal Ang II receptors are 
widely distributed both on the renal vasculature and on 
several segments of the nephron [19]. 
If several studies have investigated the ability of various 
ARBs to block the vascular effects of Ang II in humans, 
no study has assessed whether the same doses of ARB are 
able to block the renal hemodynamic and tubular effects 
of Ang II as effectively. Thus, it may well be that the 
doses of ARB effective to inhibit the BP response to 
exogenous Ang II do not inhibit the intrarenal effects of 
the peptide as efficiently. A discrepancy between the 
vascular and the renal effects of ARBs may be particularly 
relevant when ARBs are prescribed with a thiazide 
diuretic in order to activate the RAS [20]. So far, the 
impact of combining a diuretic to ARBs on the capacity of 
these agents to inhibit AT1 receptors has never been 
investigated in humans. Therefore, the main objectives 
of the present study were to investigate the impact of the 
coadministration of a thiazide diuretic on the vascular and 
renal tubular blockade of the AT1 receptor antagonist 
irbesartan and to compare the vascular and the tubular 
blockade of AT1 receptors induced by different ARBs 
combined with 25 mg of hydrochlorothiazide (HCTZ). 
Participants and methods 
Participants 
Thirty healthy, normotensive, male volunteers were 
enrolled in this study. Before inclusion, ail volunteers 
underwent a complete physical examination, a detailed 
medical history was taken, and routine laboratory tests 
Fig. 1 
Ang Il 
infusion 
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were performed. After explaining the nature and purpose 
of the study, informed written consent was obtained from 
each participant. The protocol was approved by the local 
institutional review committee (Ethical Committee of 
the Canton de Vaud, Lausanne, Switzerland). 
Study design 
ln this single-blind, randomized, two-period study, partici-
pants were randomly allocated to receive two treatments 
for 1 week separated by a 1-week washout period as shown 
in Fig. 1. Following treatments were randomized: irbesar-
tan 300 mg, irbesartan 300 mg combined with HCTZ 
12.5 or 25 mg, losartan 100 mg+ 25 HCTZ, valsartan 
160 mg+ 25 mg HCTZ and olmesartan 20 mg+ 25 mg 
HCTZ. During the first period of treatment, the indivi-
duals were randomly assigned to irbesartan 300 mg once 
daily (o.d.) (n = 10), irbesartan 300mg+12.5 mg HCTZ 
(11=10) and irbesartan 300 mg+ 25 mg HCTZ (n = 9), 
enabling a comparison of the effect of adding a thiazide 
on the response to irbesartan. For the second period 
of treatment, individuals on irbesartan 300 mg were 
blindly switched to losartan 100 mg+ 25 mg HCTZ, those 
on irbesartan 300 mg+ 12.5 mg HCTZ to olmesartan 
20mg+25mg HCTZ and those on irbesartan 300mg+ 
25 mg H CTZ to valsartan 160 mg+ 25 mg H CTZ. Vol un-
teers were allowed a free sodium and water intake through-
out the study. 
Ang II receptor blockade was assessed in ail participants 
1 day before the randomization and repeated at the end of 
each study period 24 h after the last intake of study 
medication to assess the drug affect at trough. On each 
study day, individuals entered the hospital after an over-
night fast and were comfortably installed in supine 
position. One catheter was inserted into an antecubital 
vein to collect blood. A second catheter was inserted into 
an antecubital vein of the other arm to perfuse Ang II 
and para-aminohipuric acid (PAH). The vascular AT1 
Ang Il 
infusion Pre-treatment 
Ang Il infusion Treatment 1 Wash-out Treatment 2 
~~1~~-1-w_e_e_k~~D-a_l_8~~~1-w_e_e_k~~D-ay~15·~'y22 
Study design. Ang Il, angiotensin Il. 
1 h 
baseline 
Ang Il 
3 ng/kg per min 
1 h 1 h 
recovery 
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receptor blockade was assessed by measuring the BP 
response to a 1 h infusion of exogenous Ang II (Clinalfa, 
Switzerland) infused at the dose of 3 ng/kg per min, a 
dose known to increase systemic BP by about 10-
15 mmHg in healthy individuals. Blockade of renal 
AT1 receptors was assessed by measuring the changes 
in renal plasma flow using the P AH clearance technique 
as well as the changes in urinary volume, sodium, pot-
assium and endogenous lithium excretion. These 
parameters were measured for 1 h before the Ang II 
infusion, during the 1 h infusion of Ang II and for 1 h 
after the infusion (recovery period). The P AH clearance 
and the urinary electrolyte excretion were measured as 
reported previously [21]. Serum and urinary creatinine 
were measured using the Jaffe method. Endogenous 
lithium was measured as published previously [22]. 
Clearances were calculated based on the regular formula 
(Ux V /Px). BP, heart rate, body weight and safety assess-
ments were performed regularly during the study days. 
Ali potential clinical and biological side effects were 
recorded. 
Statistical analysis 
Results are expressed as mean ± SD. The statistical 
analysis was performed using the SAS system version 
8.2 (SAS lnstitute lnc., Cary, North Carolina, USA). 
Paired Student's t-test was performed to test the changes 
induced by exogenous Ang II. A P value of less than 0.05 
was considered significant. For each individual and for 
each treatment phase, the response to Ang II on treat-
ment was compared with the individual's own baseline 
response before any administration of the drug using a 
paired t-test. Because of the small number of individuals 
in each group, no direct statistical comparison within 
treatments was performed. 
Results 
Participants enrolled in this study were aged 25 ± 3 years 
and weighted 78 ± 8 kg (BMI 24 ± 2 kg/m2). Their base-
line BP was 119 ± 1/66 ± 1.2 mmHg and heart rate 
57 ± 1.4 beats/min. Their hemoglobin was 152 ± 5 g/l, 
serum crea tinine was 89 ± 7 µ,mol/! and 24-h urinary 
sodium excretion was 117 ± 11 mmol/24 h. Ali drugs were 
well tolerated, and no significant adverse event was 
recorded during the study. One individual did not com-
plete the second period of treatment. Bence, the data of 
the first period were deleted as well, leading to nine 
individuals completing the groups, irbesartan 300mg+ 
12.5 mg HCTZ and olmesartan 20 mg+ 25 mg HCTZ. As 
data of the recovery period did not provide additional 
information, they will not be presented. 
Vascular and tubular response to exogenous 
angiotensin Il at baseline 
The 1-h infusion of 3 ng/kg per min Ang II increased SBP 
and DBP by 10.9±1.1 and 13.7 ± 0.75 mmHg, respec-
tively (n = 30, P < 0.001). Rena! plasma flow decreased 
from 685 ± 37 to 423 ± 17 ml/min (P < 0.001) and creati-
nine clearance diminished from 141 ± 7 to 130 ± 4 ml/min 
(P = 0.05). At the tubular level, Ang II significantly 
decreased urinary output (from 8.0 ± 0.5 to 1.3 ± 0.1 ml/ 
min, P < 0.001), urinary sodium excretion (from 192 ± 15 
to 64 ± 5 µ,mol/min, P < 0.001) and endogenous lithium 
clearance (from 22.8±1.9 to 10.5 ± 0.9 ml/min, 
P < 0.001), and the fractional distal excretion of Na 
(FDRNa) increased from 93 ± 0.5 to 95 ± 0.5% 
(P< 0.001). 
Effect of adding hydrochlorothiazide on the vascular 
and tubular angiotensin Il, type 1 receptor blockade 
induced by irbesartan 
The impact of irbesartan 300 mg given alone or in associ-
ation with 12.5 and 25 mg of HCTZ on the BP and renal 
hemodynamic and tu bular responses to Ang II is presented 
in Table 1. The BP response to Ang II was blocked 
completely with ail three regimens with no difference 
between the groups. The effect of Ang II on renal plasma 
flow was also blocked by more than 80% with irbesartan 
300 mg and irbesartan 300 mg+ 12.5 mg HCTZ and irbe-
sartan 300 mg+ 25 mg HCTZ. The Ang II-induced 
decrease in creatinine clearance was abolished with ail 
three regimens. Ang II significantly decreased urinary 
Table 1 Effect of increasing doses of hydrochlorothiazide combined with blockade of angiotensin Il, type 1 receptor induced by irbesartan on 
the vascular and renal response to angiotensin Il infusion 
Parameters\drug regimen 
Blood pressure response (mmHg) 
Systolic 
Diastolic 
Changes in ERPF (ml/min) 
Changes in creatinine clearance (ml/min) 
Changes in urine output (ml/min) 
Changes in urinary Na excretion (µ,mol/min) 
Changes in lithium clearance (ml/min) 
Baseline response 
Io Ang Il (n=30) 
10.9±1.1*** 
13.7±0.7*** 
-267 ±30*** 
-11 ±5** 
-6.7±0.5** 
-128± 13*** 
-12.3± 1.2*** 
lrbesartan 
300 mg (n= 10) 
0.3±1.2### 
0.3±0.511## 
-19.6±3CH 
4±10 
-5.2 ± 0.9**·" 
-26±17## 
-5.5 ± 1.4**·"" 
lrbesartan 
300mg+12.5mg 
HCTZ (n=9) 
-1.4 ±.18### 
-0.3 ± 1.0### 
36±36### 
15±14 
-3.1 ±1.2* 
-34± 17*·## 
-3.1 ± 1 .2*·## 
lrbesartan 
300mg+25mg 
HCTZ (n=10) 
0.3±1.1### 
0.4±0.8### 
-64±34## 
12±8 
-3.8 ± 1.0**·# 
-31±12*·### 
-3.8 ± 1.0*·# 
Ang 11, angiotensin Il; ERPF, effective renal plasma flow; HCTZ, hydrochlorothiazide. * P < 0.05 pre·Ang Il vs. under Ang Il on treatment. ** P < 0.01 pre·Ang Il vs. under Ang 
Il on treatment. *** P< 0.001 pre·Ang Il vs. under Ang Il on treatment. # P< 0.05 Ang 11-induced change under treatment vs. change al baseline for the same individuals. 
## P < 0.01 Ang IHnduced change under treatment vs. change al baseline for the same individuals. ### P < 0.001 Ang IHnduced change under treatment vs. change al 
baseline for the same individuals. 
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output in individuals receiving irbesartan 300 mg alone or 
with HCTZ whatever the dose, although the effect was 
blunted compared with pretreatment. Upon adminis-
tration of irbesartan 300 mg, the antinatriuretic effect of 
exogenous Ang II was significantly reduced, but some 
antinatriuretic effect of Ang II was still observed in indi-
viduals receiving irbesartan and HCTZ (P < 0.05), 
although the effect was again blunted when compared 
with the pretreatment response. The fractional excretion 
of lithium (FELi) decreased significantly upon adminis-
tration of Ang II. Under irbesartan alone, FELi also 
decreased upon infusion of Ang II (P = 0.005). Sorne 
significantly Ang II-induced decrease in FELi was 
observed in individuals receiving irbesartan combined 
with 12.5 and 25 mg HCTZ (P < 0.05 for bath). Of note, 
after 1 week ofirbesartan, FELi increased to 27%, and with 
the coadministration of HCTZ, FELi tended to decrease 
progressively with the higher dose of HCTZ (21% with 
12.5 mg HCTZ and 16.6% with 25 mg HCTZ). 
Comparative effects of various angiotensin Il receptor 
blockers on the vascular and tubular response to 
exogenous angiotensin Il 
After 1 week of administration of an ARB + 25 mg 
HCTZ, BP did not decrease significantly with irbesartan. 
However, small but significant decreases in SBP were 
observed with losartan + HCTZ (from 119 ± 2.3 to 
114 ± 2.6 mmHg, n = 10, P = 0.01 vs. pretreatment) and 
valsartan + HCTZ (from 119 ± 2.1 to 115 ± 2. 7 mmHg, 
11=10, P = 0.04). Olmesartan induced the greatest 
decrease in SBP and DBP from 119/69±1.5/1.5 to 112/ 
57 ± 3.2/1.8 mmHg (11=9, P = 0.05/0.01). 
The systemic and renal hemodynamic responses to 
Ang II in individuals receiving various ARBs in associ-
ation with 25 mg HCTZ are shown in Fig. 2. At trough, 
the BP response to exogenous Ang II was completely 
blocked by irbesartan and olmesartan and to a lesser 
degree, although significantly, with valsartan and losar-
tan. Almost similar results were obtained when the 
changes in effective renal plasma flow (ERPF) were 
assessed. The Ang II-induced change in ERPF was 
completely blocked in individuals receiving irbesar-
tan + 25 mg HCTZ and those receiving olmesar-
tan + 25 mg HCTZ when compared with pretreatment. 
In contrast, the renal hemodynamic response to exogen-
ous Ang II was still present, though blunted, in individ-
uals receiving losartan and valsartan + HCTZ. As shown 
in Fig. 3, the Ang II-induced fall in urine output was 
significantly blunted in individuals receiving irbesartan, 
olmesartan and even losartan, whereas in the valsartan 
group, Ang II still induced a marked decrease in urine 
output that was equivalent to the pretreatment response. 
The overall antinatriuretic effect of Ang II as well as the 
effect of Ang II on proximal sodium reabsorption, 
measured indirectly by the lithium clearance, were sig-
nificantly decreased by all ARBs when combined with 
Angiotensin Il receptor blockade in humans Coltamai et al. 523 
Fig. 2 
BP response to Ang Il 
(mmHg) 
16 
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Change in ERPF (ml/min) 
in response to Ang Il # 
50 
0 
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Vals 160 Los 100 
+HCTZ 25 +HCTZ 25 
Pre-treatrnent lrb 300 Olrn 20 Vals 160 Los 100 
+HCTZ 25 +HCTZ 25 +HCTZ 25 +HCTZ 25 
(n = 30) (n = 10) (n = 9) (n = 10) (n = 10) 
Comparative effects of irbesartan 300 mg, olmesartan 20 mg, valsartan 
160 mg and losartan 1 OO mg, ail combined with 25 mg 
hydrochlorothiazide on the blood pressure (upper panel) and renal 
hemodynamic response (ERPF) ta a 1-h infusion of angiotensin Il (3 ng/ 
kg per min). n=30 for the pretreatment value and n=9-10 for each 
treatment group. *P<0.05, **P<0.01,:~re-Ang Il vs. under Ang Il 
under treatment. #p< 0.05, ##p< 0.01, ililp< 0.001: Ang-11-induced 
change under treatment vs. Ang IHnduced change al baseline for the 
same individuals. Ang Il, angiotensin Il; BP, blood pressure; ERPF, 
effective renal plasma flow; HCTZ, hydrochlorothiazide; lrb, irbesartan; 
Los, losartan; Olm, olmesartan; Vals, valsartan. 
25 mg HCTZ. However, the intensity of the blockade 
was more pronounced with irbesartan and olmesartan. 
Discussion 
Ang II receptor blockers have been well characterized for 
their ability to black the BP response to exogenous Ang II 
and to lower BP in hypertension [1]. Combining a thia-
zide diuretic with an ARB is known to increase the 
antihypertensive efficacy of the ARB because the diuretic 
induces salt depletion and BP becomes more dependent 
on the activity of the RAS. To our knowledge, it has never 
been investigated in humans whether adding a thiazide 
diuretic modifies the intensity of the AT1 receptor block-
ade induced by ARBs. Our results show the following. 
First, adding a thiazide diuretic does not affect the ability 
of irbesartan to blunt the BP response to exogenous Ang 
II by more than 90%. At trough, there are, however, 
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 
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Fig. 3 
Changes in urine output 
in response to Ang Il 
0.0 r-=o".,,,---
-1.0 
-2.0 
-3.0 
(ml/min) _4.0 
--5.0 
-6.0 
-7.0 
-8.0 **·• 
Changes in sodium excretion 
in response to Ang Il 
0 
-10 
-20 
--30 
(%) 
·40 
-50 
-60 
-70 
*** 
Changes in lithium clearance 
in response to Ang Il 
0 
-2 
-4 
-6 
(ml/min) 
-8 
-10 
-12 
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Comparative effects of irbesartan 300 mg, olmesartan 20 mg, valsartan 
160 mg and losartan 1 OO mg, ail combined with 25 mg 
hydrochlorothiazide on the angiotensin 11-induced changes in urine 
output (upper panel), urinary sodium excretion (middle panel) and 
endogenous lithium clearance (lower panel). n = 30 for the 
pretreatment value and n = 9-10 for each treatment group. *P< 0.05, 
**P< 0.01, ***P< 0.001: pre-Ang Il vs. under Ang Il under treatrnent. 
11P<0.05, ##P<0.01, 111111P<0.001: Ang·ll induced change under 
treatment vs. Ang IHnduced change at baseline for the sarne 
individuals. Ang Il, angiotensin Il; HCTZ, hydrochlorothiazide; lrb, 
irbesartan; Los, losartan; Olm, olmesartan; Vals, valsartan. 
differences between ARBs combined with HCTZ that 
are likely due to their pharmacological properties. Sec-
ond, the blockade of the systemic BP response to Ang II 
and the blockade of the renal hemodynamic response to 
Ang II go in parallel. Our data also show that there are 
marked differences between ARBs in their ability to the 
black the vascular effects of Ang II at trough. Third, the 
renal tubular effects of Ang II are blunted by ail ARBs 
independently of the presence or the absence of the 
thiazide. However, the intensity of blockade of the 
tubular effects of exogenous Ang II appears to be Jess 
complete than that obtained at the vascular level, with 
only 50-75% inhibition depending on the ARB. Taken 
together, these findings support our hypothesis that the 
intensity of Ang II receptor blockade induced by ARBs is 
not identical at the vascular and tubular level. Adding a 
thiazide diuretic to an ARB does not appear to have a 
major impact on the capacity of these agents to black A'l'i 
receptors. However, our results confirm previous obser-
vations, suggesting that there are differences among 
ARBs in their ability to black the RAS at trough. 
Assessing the response to exogenous angiotensin I or II is 
an effective means to investigate the degree of RAS 
blockade induced by ACE inhibitors or Ang II receptor 
black.ers in humans [4,23,24]. In contrast to our previous 
studies, Ang II was infused for 1 h at a fixed dose in order 
to be able to investigate its renal hemodynamic and 
tubular effects as well as the systemic vascular effects. 
As expected, Ang Il induced a consistent and reprodu-
cible increase in BP, and in the kidney, Ang II signifi-
cantly decreased renal plasma flow. Ang II also produced 
the expected decrease in urinary volume and sodium 
excretion, the latter being mediated essentially by an 
increase in proximal sodium reabsorption as reflected by 
the decrease in FELi. 
As sait intake is known to modulate the production of 
renin and hence the expression of Ang II receptors [20], it 
appears to us of importance to examine whether a thia-
zide could actually modify the degree of Ang II receptor 
blockade induced by ARBs. In accordance with our ear-
lier observations in the absence of diuretics [4,25], the BP 
response to exogenous Ang II measured 24 h after dosing 
was blocked by more than 90% with irbesartan and 
olmesartan even when combined with HCTZ, suggesting 
that the diuretic had little, if any, impact on the ability of 
ARBs to black vascular AT1 receptors. A substantial 
vascular blockade was also observed with losartan and 
valsartan when combined with HCTZ, but the effect of 
these two ARBs at 24 h tended to be smaller, an obser-
vation which goes along with their known shorter half-life 
and their Jack of 24h AT1 receptor blockade [l,3,4]. Of 
note, in this study, ail drugs were prescribed at their 
maximal recommended doses in combination with 
HCTZ in our country at the time of study. 
'Vhat is true for BP may not be for the renal protective 
effect of ARB. Thus, although the contrai of a high BP 
represents a major step to retard the progression of renal 
diseases, several studies have demonstrated that a more 
intensive blockade of the RAS results in a greater 
decrease in proteinuria, mainly in patients with type 2 
diabetes. In this context, an intensive RAS blockade 
has been obtained either with the combination of an 
ACE inhibitor and an ARB [15,17,26] or with the use 
ofhigher doses of ARB [11-14], or more recentlywith the 
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association of an ARB and a renin inhibitor [18]. The 
favorable impact of higher doses of ARB on renal fonction 
might actually reftect the fact that ARB-induced AT1 
receptor blockade does not develop in parallel in the 
vessels and in the kidney, and that higher drug doses may 
be needed to block the renal RAS owing to the higher 
concentrations of Ang II formed in the kidney. ln this 
respect, Vos et al. [27] have reported previously that the 
renal vasoconstrictor response to angiotensin 1 was main-
tained in . volunteers receiving 20-mg enalapril twice 
daily, suggesting that this dose, which blacks the BP 
effects of angiotensin 1, was not able to block the intra-
renal RAS. The findings of our study further support this 
hypothesis. lndeed, the renal hemodynamic and tubular 
effects of exogenous Ang II did not appear to be blocked 
in parallel to the inhibition of the BP response to Ang II 
depending on the ARB. Thus, longer acting ARBs, such 
as irbesartan and olmesartan, blocked the Ang II-induced 
renal vasoconstriction as effectively as the BP response to 
Ang II, but this was clearly not the case for valsartan and 
losartan which induced only a partial blockade of the 
renal vasoconstriction, which was clearly less intense than 
their impact on the BP response to Ang IL 
The discrepancy between the vascular and the intrarenal 
blockade of AT1 receptors was even greater when con-
sidering the tubular response to exogenous Ang IL The 
antinatriuretic and antidiuretic effects of Ang II were 
blunted by ail antagonists but to a lesser degree than at 
the vascular level. This was particularly relevant for the 
impact on the Ang II-induced decrease in urine output 
and urinary sodium excretion. This observation goes 
along with the measurement of greater concentrations 
of Ang II in the proximal segments of the nephron [19]. 
Of note, the addition of a thiazide diuretic was associated 
with a slight increase in proximal sodium reabsorption as 
evidenced by a lower clearance of endogenous lithium 
(16 ml/min) after 1 week of administration compared with 
pretreatment values (22.8 ml/min). This decrease may 
actually be the consequence of the lower systemic BP but 
may also be a proximal compensatory mechanism pre-
venting an excessive loss of sodium. 
Our results confirm that there are important differences 
between ARBs prescribed at their maximal recommended 
doses even when they are combined with a thiazide 
diuretic. The data clearly confirm our initial findings that 
neither valsartan nor losartan provide a 24-h blockade of 
AT receptors at 160 and lOOmg/day, respectively [2,3]. 
Since then, some studies have demonstrated that higher 
doses could actually improve their effect on BP and 
proteinuria. This is the case, for example, of valsartan, 
which appears to have a greater renal efficacy when used at 
doses up to 640 mg [12]. ln our experimental setting, 
olmesartan 20 mg+ 25 mg HCTZ had the greatest impact 
on BP and renal parameters, followed very closely by 
irbesartan 300 mg+ 25 mg H CTZ. 
Angiotensin Il receptor blockade in humans Coltamai et al. 525 
ln conclusion, ARBs do not appear to block renal AT1 
receptors as effectively as vascular receptors, and the 
addition of a thiazide diuretic does not affect their ability 
to block AT1 receptors. Our findings are in accordance 
with the clinical observation that higher doses of ARB 
might be needed in order to lower proteinuria and to 
protect kidney fonction. Moreover, our results confirm 
that there are significant differences between ARBs in 
their ability to induce a sustained vascular and renal 
tubular blockade of Ang II receptors. These factors 
should be taken into account when designing future renal 
protection trials. 
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